These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 20805403)

  • 21. An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug.
    SMITH MR; WOOD WB
    J Exp Med; 1956 Apr; 103(4):509-22. PubMed ID: 13306859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sharpening Host Defenses during Infection: Proteases Cut to the Chase.
    Marshall NC; Finlay BB; Overall CM
    Mol Cell Proteomics; 2017 Apr; 16(4 suppl 1):S161-S171. PubMed ID: 28179412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging bacterial pathogens: the past and beyond.
    Vouga M; Greub G
    Clin Microbiol Infect; 2016 Jan; 22(1):12-21. PubMed ID: 26493844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New technologies, human-microbe interactions, and the search for previously unrecognized pathogens.
    Relman DA
    J Infect Dis; 2002 Dec; 186 Suppl 2():S254-8. PubMed ID: 12424706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High throughput genomic and proteomic technologies in the fight against infectious diseases.
    Tanca A; Deligios M; Addis MF; Uzzau S
    J Infect Dev Ctries; 2013 Mar; 7(3):182-90. PubMed ID: 23492995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MALDI-TOF MS for the diagnosis of infectious diseases.
    Patel R
    Clin Chem; 2015 Jan; 61(1):100-11. PubMed ID: 25278500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomics of bacterial pathogenicity: therapeutic implications.
    Windle HJ; Brown PA; Kelleher DP
    Proteomics Clin Appl; 2010 Feb; 4(2):215-27. PubMed ID: 21137045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can metabolomics learn from genomics and proteomics?
    Arita M
    Curr Opin Biotechnol; 2009 Dec; 20(6):610-5. PubMed ID: 19850466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bacterial biofilms in infectious diseases].
    Tapiainen T; Salo J; Uhari M
    Duodecim; 2010; 126(7):765-72. PubMed ID: 20597324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Opportunistic microbes and their role in infectious pathology].
    Tokarevich KN
    Tr Inst Im Pastera; 1983; 61():50-60. PubMed ID: 6678513
    [No Abstract]   [Full Text] [Related]  

  • 31. Microbe hunting in laboratory animal research.
    Palacio G; Briese T; Lipkin WI
    ILAR J; 2010; 51(3):245-54. PubMed ID: 21131725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibiotic strategy in an infectious diseases unit].
    Dupon M
    Presse Med; 2000 Jan; 29(2):121-3. PubMed ID: 10682044
    [No Abstract]   [Full Text] [Related]  

  • 33. Mass spectrometry-based proteomic approaches to study pathogenic bacteria-host interactions.
    Yang Y; Hu M; Yu K; Zeng X; Liu X
    Protein Cell; 2015 Apr; 6(4):265-74. PubMed ID: 25722051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogens.
    Fogg MJ; Alzari P; Bahar M; Bertini I; Betton JM; Burmeister WP; Cambillau C; Canard B; Corrondo MA; Coll M; Daenke S; Dym O; Egloff MP; Enguita FJ; Geerlof A; Haouz A; Jones TA; Ma Q; Manicka SN; Migliardi M; Nordlund P; Owens RJ; Peleg Y; Schneider G; Schnell R; Stuart DI; Tarbouriech N; Unge T; Wilkinson AJ; Wilmanns M; Wilson KS; Zimhony O; Grimes JM
    Acta Crystallogr D Biol Crystallogr; 2006 Oct; 62(Pt 10):1196-207. PubMed ID: 17001096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical applications of bacterial glycoproteins.
    Fulton KM; Smith JC; Twine SM
    Expert Rev Proteomics; 2016; 13(4):345-53. PubMed ID: 26971465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Montpellier Infectious Diseases (MID), 2nd annual meeting (2012).
    Bastien P; Braun-Breton C; Chazal N; Devaux C; Foulongne V; Frank M; Hernandez JF; Kremer L; Lebrun M; Le Moing V; Leonetti JP; Lionne C; Peyrottes S
    Infect Genet Evol; 2013 Jun; 16():450-4. PubMed ID: 23416259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The necessity to revise Koch's postulates and its application to infectious and non-infectious diseases: a mini-review.
    Hosainzadegan H; Khalilov R; Gholizadeh P
    Eur J Clin Microbiol Infect Dis; 2020 Feb; 39(2):215-218. PubMed ID: 31440916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomics progresses in microbial physiology and clinical antimicrobial therapy.
    Chen B; Zhang D; Wang X; Ma W; Deng S; Zhang P; Zhu H; Xu N; Liang S
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):403-413. PubMed ID: 27812806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass Spectrometry Techniques in Emerging Pathogens Studies: COVID-19 Perspectives.
    Mahmud I; Garrett TJ
    J Am Soc Mass Spectrom; 2020 Oct; 31(10):2013-2024. PubMed ID: 32880453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage.
    Pirofski LA; Casadevall A
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.